Evolent Health, Inc (NYSE:EVH) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Evolent Health, Inc (NYSE:EVH) have been given a consensus rating of “Moderate Buy” by the sixteen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $12.8571.

A number of research analysts recently issued reports on EVH shares. BMO Capital Markets started coverage on shares of Evolent Health in a research note on Thursday. They issued an “outperform” rating and a $7.00 price target for the company. BTIG Research lowered their price target on Evolent Health from $20.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Stephens upgraded Evolent Health from an “equal weight” rating to an “overweight” rating and set a $7.00 price objective for the company in a research report on Thursday. Zacks Research raised shares of Evolent Health from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Finally, Canaccord Genuity Group reduced their price target on Evolent Health from $16.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday.

Institutional Trading of Evolent Health

Several institutional investors have recently made changes to their positions in the stock. Schonfeld Strategic Advisors LLC bought a new position in Evolent Health during the third quarter worth about $2,191,000. Rubicon Founders LLC bought a new stake in shares of Evolent Health during the 3rd quarter valued at $49,204,000. Shay Capital LLC acquired a new position in Evolent Health in the third quarter valued at about $254,000. Two Sigma Investments LP grew its holdings in Evolent Health by 133.8% during the third quarter. Two Sigma Investments LP now owns 851,138 shares of the technology company’s stock valued at $7,201,000 after purchasing an additional 487,026 shares during the period. Finally, Concentric Capital Strategies LP bought a new stake in shares of Evolent Health in the 3rd quarter valued at $376,000.

Evolent Health Price Performance

Shares of EVH opened at $4.17 on Friday. Evolent Health has a 1-year low of $4.01 and a 1-year high of $13.61. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.01 and a quick ratio of 1.01. The firm has a market capitalization of $489.42 million, a PE ratio of -2.59 and a beta of 0.58. The company’s fifty day moving average price is $7.66 and its 200-day moving average price is $8.88.

Evolent Health (NYSE:EVH) last released its quarterly earnings results on Tuesday, June 4th. The technology company reported $0.21 earnings per share for the quarter. Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The company had revenue of $427.70 million during the quarter. On average, equities research analysts predict that Evolent Health will post 0.08 EPS for the current year.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.